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Abstract
Background: Domains are basic units of proteins, and thus exploring associations between protein domains and
human inherited diseases will greatly improve our understanding of the pathogenesis of human complex diseases
and further benefit the medical prevention, diagnosis and treatment of these diseases. Within a given domain-
domain interaction network, we make the assumption that similarities of disease phenotypes can be explained
using proximities of domains associated with such diseases. Based on this assumption, we propose a Bayesian
regression approach named “domainRBF“ (domain Rank with Bayes Factor) to prioritize candidate domains for
human complex diseases.
Results: Using a compiled dataset containing 1,614 associations between 671 domains and 1,145 disease
phenotypes, we demonstrate the effectiveness of the proposed approach through three large-scale leave-one-out
cross-validation experiments (random control, simulated linkage interval, and genome-wide scan), and we do so in
terms of three criteria (precision, mean rank ratio, and AUC score). We further show that the proposed approach is
robust to the parameters involved and the underlying domain-domain interaction network through a series of
permutation tests. Once having assessed the validity of this approach, we show the possibility of ab initio inference
of domain-disease associations and gene-disease associations, and we illustrate the strong agreement between our
inferences and the evidences from genome-wide association studies for four common diseases (type 1 diabetes,
type 2 diabetes, Crohn’s disease, and breast cancer). Finally, we provide a pre-calculated genome-wide landscape
of associations between 5,490 protein domains and 5,080 human diseases and offer free access to this resource.
Conclusions: The proposed approach effectively ranks susceptible domains among the top of the candidates, and
it is robust to the parameters involved. The ab initio inference of domain-disease associations shows strong
agreement with the evidence provided by genome-wide association studies. The predicted landscape provides a
comprehensive understanding of associations between domains and human diseases.
Background
Over the past few decades, remarkable success has been
achieved for such traditional gene-mapping approaches
as family-based linkage analysis [1,2] and population-
based association studies [3,4] in pinpointing genes that
are responsible for human inherited diseases [5,6].
Nevertheless, these traditional methods are either only
capable of linking diseases with genetic regions that
typically contain dozens to hundreds of genes, or usually
require carefully selected candidate genes that are biolo-
gically related to the disease under investigation [5,6].
Consequently, the development of computational meth-
ods for the inference of genes and their protein products
that are truly responsible for the disease of interest has
been one of the major tasks in human genetics and
functional genomics [7-18]. Particularly, a protein typi-
cally consists of several structural domains, each of
which is closely related to a specific function of the pro-
t e i n .T h e r e f o r e ,t h ei n f e r e n c eo fc a u s a t i v eg e n e sc o u l d
be aided by first dividing products of candidate genes
into discrete domains with known functions and struc-
tural features and then infer the association of these
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any medium, provided the original work is properly cited.domains to the disease of interest [19-21]. Following this
direction, a new protein domain called PAAD has been
discovered to be associated with apoptosis, cancer, and
autoimmune diseases [19], and a novel domain called
G8 has been reported to be linked to polycystic kidney
disease and non-syndromic hearing loss [20]. However,
most of these discoveries have thus far been made with
the assistance of protein sequence analysis and other
experimental techniques. Even though such findings are
significant, the associations reported are still very spora-
dic. Therefore, it would be helpful to develop computa-
tional methods to directly infer possible associations
between domains and human diseases.
It has been shown that deleterious nonsynonymous
single nucleotide polymorphisms (nsSNPs) that are
responsible for a specific disease of interest may change
structures of some protein domains, affect functions of
corresponding proteins, and further result in the disease
under investigation. Therefore, existing associations
between domains and diseases can be constructed by
bridging protein domains that contain known deleter-
ious nsSNPs and human diseases with which the
nsSNPs are associated [22]. Furthermore, recent
advances in computational functional genomics have
enabled the large-scale prediction of domain-domain
interactions and have led to repositories of known and
predicted domain-domain interactions such as DOMINE
[23] and InterDom [24,25]. Accordingly, large-scale
inference of unknown associations between domains
and human diseases can be performed by using these
data sources. For example, one of our previous studies
[22] adopted the “guilt-by-association” principle [26] to
compute scores that quantify the strength of associa-
tions between a query disease and candidate domains
from domain-domain interaction data and known asso-
ciations between the query disease and other domains,
and then rank candidate domains according to their
scores. However, the scope of application of this
approach is limited because the “guilt-by-association”
principle relies on known associations between the
query disease and domains to infer novel associations
for the query disease. Under these conditions, the
method cannot be applied to diseases whose genetic
bases are completely unknown.
Recent studies on the modular nature of human
genetic diseases have shown that diseases share common
clinical characteristics are often caused by functionally
related genes [16,27]. With the application of text
mining techniques, it has also been possible to calculate
pair-wise similarities for most human disease pheno-
types [28]. With these advances, various methods have
been proposed to prioritize candidate genes through the
combined use of disease phenotype similarity and gene
proximity [7,8,29-32]. Inspired by the successes of these
methods, we propose in this paper to infer associations
between domains and human disease phenotypes based
on the assumption that phenotypically similar diseases
are caused by functionally related domains. More speci-
fically, we resort to a linear regression framework to
model the relationship between a domain proximity pro-
file and a phenotype similarity profile, and we develop a
Bayesian regression approach, called domainRBF
(domain Ranking with Bayes Factor), to calculate Bayes
factors that quantify the strength of associations
between corresponding domain proximity profiles and
phenotype similarity profiles.
We compile a set of known domain-disease associa-
tions using the Pfam database [33] and annotations of
nsSNPs in the UniProt database [34,35], extract a
domain-domain interaction network from the DOMINE
database [23] as well as the InterDom database [24,25],
and then download a pre-calculated phenotype similarity
network [28]. Using these data, we show that domain
proximities calculated from a domain-domain interac-
tion network do, indeed, imply phenotype similarities of
diseases. We next validate the approach and evaluate its
performance using three criteria: precision, mean rank
ratio, and AUC score. To accomplish this, we apply
three large-scale leave-one-out cross-validation experi-
ments against random control, simulated linkage inter-
val, and genome-wide scan with two domain proximity
measures: diffusion kernel and shortest path with Gaus-
sian kernel. Results show that the proposed approach
can successfully recover known associations between
domains and human diseases. We further show the
robustness of this approach to the parameters involved
and the underlying domain-domain interaction network
through a series of permutation tests. Having success-
fully assessed the validity and robustness of this
approach, we can then infer domain-disease in an ab
initio way and illustrate the strong agreement of the
inference results with evidence of genome-wide associa-
tion studies for four common human diseases, including
type 1 diabetes, type 2 diabetes, Crohn’sd i s e a s e ,a n d
breast cancer. We further demonstrate the possibility of
inferring gene-disease associations from domain-disease
associations. Finally, we calculate a genome-wide land-
scape of associations between 5,490 domains and 5,080
human diseases using all known domain-disease associa-
tions, and we provide a freely accessible website for this
resource.
Methods
Overview of the DomainRBF approach
We ground the inference of domains that are associated
with human inherited diseases on a set of known
domain-disease associations that are compiled from the
Pfam database [33] and annotations of nsSNPs in the
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network extracted from the DOMINE database [23] and
the InterDom database [24,25], as well as a pre-calcu-
lated phenotype similarity network containing pair-wise
similarity scores among more than 5,000 human genetic
disease phenotypes in the OMIM database [28].
Based on the assumption that phenotypically similar
diseases are caused by functionally related domains, we
propose a linear regression framework to model the
relationship between a domain proximity profile and a
phenotype similarity profile, and we resort to a Bayesian
approach to solve the linear regression model. As shown
in Figure 1 (inspired by Ideker and Sharan [36]), given a
query phenotype p and the pre-calculated pair-wise
similarity scores between phenotypes, we extract scores
between the query phenotype and all other phenotypes
that have at least one associated domain and obtain a
phenotype similarity profile for the query phenotype.
On the other hand, for a query domain d in a set of
candidate domains, we resort to the domain-domain
interaction network to calculate proximity scores of the
query domain to all domains that are known to be asso-
ciated with some phenotypes and further calculate a
domain proximity profile. With these two profiles, we
propose a Bayesian regression approach called
domainRBF (domain Ranking with Bayes Factor) to cal-
culate a Bayes factor that quantifies the strength of asso-
ciation between the query domain and the query
phenotype, using the phenotype similarity profile as the
response variable and the domain proximity profile as
the predictor variable. Finally, we rank candidate
domains according to their corresponding Bayes factors
and obtain a rank list of the candidates.
Data sources
Domain-disease associations
A domain is defined as associated with a disease if the
domain contains at least one nonsynonymous single
nucleotide polymorphism (nsSNP) associated with the
disease [22]. Therefore, associations between domains
and diseases are obtained by combining known associa-
tions between nsSNPs and diseases as well as relation-
ships between protein and domains.
Known associations between nsSNPs and diseases
are obtained from annotations of nsSNPs in the Uni-
Prot database [34,35], in which nsSNPs are classified
into three categories: disease, polymorphism, and
unclassified. In version 57.15 (released on March 2,
2010) of this database, 23,372 nsSNPs belong to the
disease category, 36,303 belong to the polymorphism
category, and the remaining 2,019 nsSNPs are cur-
rently unclassified. For each of the nsSNPs in the dis-
ease category, the entry ID of the specific disease in
the OMIM database is also provided. Consequently,
we obtain 19,552 associations between 19,552 nsSNPs
and 1,592 diseases.
Figure 1 Scheme of the proposed domainRBF approach. Texts in addition to pink arrows denote the pipeline of the domainRBF approach.
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are obtained from the Pfam database [33], which pro-
vides a large collection of both high quality protein
domain families (Pfam-A) and low quality protein
domain families (Pfam-B). In version 24.0 of the Pfam-A
collection (released in October 2009), 11,912 domain
families that cover more than 75.15% of known proteins
are collected. Using this data source, we obtain 96,276
relationships between 4,324 domains and 66,498 human
proteins.
Using the above data sources and having defined a
domain as associated with a disease if the domain con-
tains at least one nsSNP associated with the disease, we
are able to establish 1,614 associations between 671
domains and 1,145 diseases.
Domain-domain interaction networks
Our inference of domain-disease associations is based
on domain-domain interaction networks extracted from
the DOMINE [23] and InterDom [24,25], two of the
most widely-used databases of known and predicted
domain-domain interactions.
The latest version of DOMINE (released in February
2008) contains a total of 20,513 domain-domain interac-
tions, out of which 4,349 (gold-standard positives) are
inferred from PDB entries (the union of the sets of
interactions from iPfam [37] and 3did [38,39]), and
17,781 are predicted by at least one computational
approach of 8 different computational approaches using
Pfam domain definitions. Of the 17,781 predicted inter-
actions, there are 3,143 high-confidence predictions
(predicted by ME [40] or at least two different
approaches), 729 medium-confidence predictions (het-
ero-domain interactions in which both domains have
the same annotations in the biological process of the
gene ontology), and 13,909 remaining low-confidence
predictions [23].
The latest version of InterDom (released in July 31,
2007) contains a total of 148,938 domain-domain inter-
actions, out of which 7,718 are inferred from PDB
entries [41], 143,820 are inferred from BIND [42] and
DIP [43] entries, and 4,631 are inferred from the
domain fusion hypothesis. InterDom further uses a
probabilistic scoring system to give confidence scores to
domain interactions that are derived independently by
multiple methods from different data sources. Finally,
interactions with 90%, 75%, 50%, and 25% confidence
levels are provided [24,25].
In our work, we use two domain-domain interaction
networks extracted from these data. First, we discard
singletons in the PDB part of the DOMINE database
[23] and obtain a small network that is composed of
2,285 interactions between 1,971 domains (2.32 interac-
tions per domain on average). Second, we combine
37,177 interactions whose confidence scores are at least
90% in the InterDom database and all interactions in
the DOMINE databases to obtain a large domain-
domain interaction network that is composed of 48,778
interactions between 5,490 domains (17.77 interactions
per domain on average).
The phenotype similarity network
The phenotype similarity network of human diseases is
a fully connected network obtained from an earlier
work of van Driel et al.[ 2 8 ] ,i nw h i c ht h ep a i r - w i s e
relationships between 5,080 human genetic diseases
from the OMIM database are mapped. Briefly, van
Driel et al. use the anatomy (A) and the disease (C)
sections of the medical subject headings vocabulary
(MeSH) to extract terms from the OMIM database,
thus providing a standard way of presenting the
OMIM records as corresponding phenotype feature
vectors. As a result, each disease phenotype is charac-
terized by a vector of standardized and weighted phe-
notypic feature terms mapped from corresponding
OMIM records in the full text (TX) and clinical synop-
sis (CS) fields. Then, for each pair of disease pheno-
types, a similarity score is calculated by the cosine of
their feature vector angle. The reliability of the pheno-
type similarity score has been tested [28], showing that
these similarities are positively correlated with a num-
ber of measures of gene functions. The final phenotype
similarity network contains pair-wise similarity scores
for 5,080 OMIM records, covering a majority of
recorded human disease phenotypes.
The DomainRBF model
Given the phenotype similarity network, we use ypp’ to
denote the similarity score between a query disease phe-
notype p and another disease phenotype p’.W ef u r t h e r
define the phenotype similarity profile for disease phe-
notype p as yp =( ypp1,ypp2,···,yppm)T, i.e., the similari-
ties between the disease phenotype p and all m disease
phenotypes p1, p2,. . . ,pm that have at least one asso-
ciated domain.
On the other hand, given a domain-domain interac-
tion network of n nodes, we calculate the proximity
between two domains using two measures: (1) shortest
path with Gaussian kernel (SG) and (2) diffusion kernel
(DK). The shortest path proximity between two domains
u and v, SP(u,v), is defined as the length of the shortest
path between the two domains. Using the Gaussian ker-
nel, the proximity distance measure SG (u, v) is obtained
as SG(u,v) = exp{-b(SP(u,v))
2}, where b i saf r e ep a r a -
meter. The diffusion kernel for the network is defined
as K =( kuv)n×n = e
-gL,w h e r e0<g <1i saf r e ep a r a -
meter that controls the magnitude of diffusion. The
matrix L = D - A is the Laplacian of the network, where
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is the adjacency matrix of the domain-domain interac-
tion network. With the diffusion kernel K =( kuv)n×n,w e
define the diffusion proximity of two domains u and v
as DK(u,v)=kuv, i.e., the corresponding element in the
diffusion kernel. Then, let xdd’ denote the proximity
between domains d and d’ in the domain-domain inter-
action network, and let D(p)d e n o t et h es e to fd o m a i n s
known to be associated with a phenotype p.W ed e f i n e
the proximity between domain d to disease phenotype p
as the summation of proximity scores between domain
d and all domains known to be associated with disease
phenotype p, i.e., xdp = ∑d’ÎD(p) xdd’.W ef u r t h e rd e f i n e
the domain proximity profile for domain d as
xd =( xdp1,xdp2,···,xdpm)T.
Then, given a query disease phenotype p and a query
domain d, we explain the phenotype similarity profile yp
using domain proximity profile xd via a linear regression
model
y = Xβ + ε
where y = yp is the response vector, X =( 1,xd)t h e
design matrix, b = (b0, b1)
T the coefficient vector, and
ε =( ε1,..., εm)
T the residual vector. Note that the first
column of the design matrixb e i n g1 sf o rt h ep u r p o s e
of incorporating the intercept. We propose to solve
this linear regression model using a Bayesian
a p p r o a c h .W ec h o o s et ot a k eaB a y e s i a na p p r o a c h
because it provides a natural way to consider the
uncertainty in estimated parameters, and it provides
Bayes factor, a measure of the strength of evidence for
an association, which is defined as the ratio of mar-
ginal likelihoods for y conditional on X under the
alternative and the null hypothesis, respectively, as
described below.
For the alternative model, we assume that y condi-
tional on X is subject to a normal distribution, as
y|X,β,σ2 ∼ Normal(Xβ,σ2I),
with residuals independent and identically distributed,
following normal density with mean 0 and variance s
2.
We set conjugate prior distributions for b and s
2,a s
σ2 ∼ Inverse - χ2(n0,σ2
0),
and
β|σ2 ∼ Normal(μ0,σ2 0),
where μ0 = (μ0, μ1)
T is composed of prior means, and
s
2Σ0 prior variances with Σ0 =d i a g ( sμ
2,s1
2)b e i n ga
diagonal matrix. The joint distribution of all random
quantities y, b, and s
2 is then given as
p(y,β,σ2|X)
=p(y|X,β,σ2)p(β|σ2,μ0, 0)p(σ2|n0,σ2
0)
=

1
2πσ2
n/2
exp

−
yTy − 2yTXβ + βTXTXβ
2σ2

×

1
2πσ2 | 0|
1/2
exp

−
βT −1
0 β − 2βT −1
0 μ0 + μT
0 −1
0 μ0
2σ2

×
(n0σ2
0)
n0/2
 (n0/2)

1
σ2
n0/2+1
exp

−
n0σ2
0
2σ2

.
Integrating out b and s
2, we obtain the marginal like-
lihood of y given X as
p1(y|X)=

1
2π
n/2
| n|
| 0|
1/2 (nn/2)
 (n0/2)
(n0σ2
0)
n0/2
(nnσ2
n)
nn/2,
where nn = n + n0 and nn sn
2 = n0s0
2 + y
Ty + μ0
T Σ0
-
1μ0-μn
T Σn
-1μn with Σn =( X
T X + Σ0
-1)
-1 and μn = Σn
(X
T y+Σ0
-1μ0).
On the other hand, for the null model, where y is
independent of X, the marginal likelihood of y can be
derived in a similar way, as
p0(y)=

1
2π
n/2
 n
 0
1/2 (nn/2)
 (n0/2)
(n0σ2
0)
n0/2
(nn ˜ σ2
n)
nn/2,
where
 0 = σ2
μ, n =( n +1 / σ2
μ)−1,nn ˜ σ2
n = n0σ2
0 +yTy+μ2
0/σ2
μ −(n +1 / σ2
μ)−1(n¯ y + μ0/σ2
μ)2,
and ¯ y =
1
m
m
i=1 yi.
Then, the Bayes factor BF is the ratio of p1(y|X)a n d
p0(y), as
BF =
p1(y|X)
p0(y)
=

| n|
 n
1/2
| 0|
 0
−1/2
nnσ2
n
nn ˜ σ2
n
−nn/2
.
Following the literature [44], we take the limit +∞ for
sμ
2 and 0 for both n0 and s0
2, and we obtain the limit
value of the Bayes factor as
BFlim =
(n| n|)
1/2
σ1

yTy − n¯ y2
yTy − μT
n −1
n μT
n
n/2
.
For simplicity, we further set μ0 = 0 as in the litera-
ture [44], and we set s1
2 = 1 as the default setting in
this paper, although the effect of these parameters are
also studied.
Note that before the construction of the Bayesian
regression relationship between yp and xd,w ea p p l ya n
inverse-normal transform to yp to guarantee that the
responsive variable is normally distributed. As illustrated
in [45,46], the transform formula we use is:
yi =  −1(ri/(m +1 )),f o ri =1 , ... ,m
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length of yp, and F the cumulative distribution function
of the standard normal distribution.
Validation methods and evaluation criteria
On the basis of the domain-domain interaction network
and known associations between protein domains and
disease phenotypes, we proceed to validate how well the
proposed approach performs in recovering these known
associations. We adopt three large scale leave-one-out
cross-validation experiments for this purpose.
First, in the validation of random controls, we priori-
tize domains that are known to be associated with dis-
ease phenotypes (i.e., disease domains) against randomly
selected control domains. Specifically, in each run of the
validation, we select an association between a domain
and a disease phenotype, assume that the association is
unknown, and prioritize the domain against a set of 99
randomly selected control domains.
Second, in the validation of simulated linkage inter-
vals, we prioritize domains that are known to be asso-
ciated with disease phenotypes (i.e., seed domains)
against domains that are located around the seed
domains. Specifically, in each run of the validation, we
select an association between a domain and a disease
phenotype, assume that the association is unknown, and
prioritize the domain against a set of control domains
that are located within 10 Mbp upstream and down-
stream of this domain.
Third, in the validation of genome-wide scan, we
prioritize seed domains against all known domains. Spe-
cifically, in each run of the validation, we select an asso-
ciation between a domain and a disease phenotype,
assume that the association is unknown, and prioritize
the domain against all other domains in the domain-
domain interaction network.
In each of the above leave-one-out cross-validation
experiments, we repeat the validation run for every
known association between a domain and a disease phe-
notype, and we are able to obtain a number of ranking
lists. We further normalize the ranks by dividing them
by the total number of candidate domains in the rank-
ling list to obtain rank ratios and calculate the values of
three criteria to measure the performance of a prioriti-
zation method.
The first criterion is termed precision. We consider a
prediction as successful if the known disease domain is
ranked at the top (with rank 1). Then, the proportion of
successful predictions among all predictions is defined
as the precision. Obviously, a high precision suggests
that a method has high prediction power. The second
criterion is termed mean rank ratio, which is simply the
average of rank ratios for all known disease domains in
a cross-validation experiment. This criterion provides a
summary of the ranks of all domains that are known to
be associated with disease phenotypes, and the smaller
the mean rank ratio, the better a method. The third cri-
terion is termed AUC, which is the area under the recei-
ver operating characteristic curve (ROC). Given a list of
rank ratios and a predefined threshold, we define the
sensitivity as the percentage of disease domains that are
ranked above the threshold and the specificity as the
percentage of control domains that are ranked below
the threshold. By varying the threshold values, we are
able to plot a receiver operating characteristic curve,
which shows the relationship between sensitivity and 1-
specificity. Calculating the area under the ROC curve
(AUC), we are able to obtain the AUC score, which pro-
vides an overall measure for the performance of the
prioritization approach.
Results
Domain proximity implying phenotype similarity
The DomainRBF approach is based on the assumption
that similarities of disease phenotypes can be explained
by proximities of domains associated with the pheno-
types within a domain-domain interaction network via a
regression model. In order to validate this assumption,
we discard singletons in the PDB part of the DOMINE
database [23] and obtain a domain-domain interaction
network that is composed of 2,285 interactions between
1,971 domains. Focusing on these domains, we obtain
1,066 associations between 763 phenotypes and 378
domains. Then, we calculate a Bayes factor for each of
these associations, and run a Wilcoxon signed rank test
to check whether the resulting Bayes factors are signifi-
cantly greater than 1 (the random case). Results show
that the p-value is smaller than 2.2 × 10
-16, indicating
that the similarities of disease phenotypes have a strong
relationship with the proximities of associated domains.
To further substantiate this point, we perform a series
of permutations towards disease-disease, domain-dis-
ease, and domain-domain relationships. First, we break
the disease-disease relationship by permuting the pheno-
type similarity profile. Second, we break the domain-dis-
ease relationship by two methods: (1) permuting
domain-disease associations and (2) replacing domains
in known disease-domain associations with randomly
selected domains. Third, we break the domain-domain
relationship by permuting connections in the underlying
domain-domain interaction network, while keeping node
degrees and recalculating the diffusion kernel. For each
of the above permutations, we calculate Bayes factors of
disease domains and present the results in Figure 2,
which shows that the median of Bayes factors based on
the original data is much higher than the medians
obtained from the different permuted relationships, as
described above.
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domain-domain interaction network (48,778 interactions
between 5,490 domains) that includes the entire DOM-
INE database [21] and the high-confidence part of the
InterDom [22,23] database. Results show that Bayes fac-
tors for known domain-disease associations are also sig-
nificantly greater than 1, while the p-value of the
Wilcoxon signed rank test is smaller than 2.2 × 10
-16.
We further perform a series of permutation tests and
present the results [Additional file 1: Supplemental Fig-
ure S1]. Based on these comprehensive studies, our
hypothesis has been clearly demonstrated: that similari-
ties between diseases can be explained by the proximi-
ties of domains associated with such diseases within a
given domain-domain interaction network. In other
words, domain proximity implies phenotype similarity.
Performance of the DomainRBF approach
Since interactions from the PDB entries have the highest
confidence of domain-domain interactions, we first test
the validity of our approach on the PDB part of the
DOMINEdatabase [23]. We implement three large-scale
leave-one-out cross-validation experiments against ran-
dom controls, simulated linkage intervals and genome-
wide scan, respectively, each on the basis of two dis-
tance measures: diffusion kernel (DK) and shortest path
with Gaussian kernel (SG).
For each of the three validation experiments, using
either the diffusion kernel or the shortest path with
Gaussian kernel, we draw a histogram of rank ratios for
the entire 1,066 known associations, as shown in Figure
3 .F r o mt h ef i g u r ew es e et h a tr a n kr a t i o sa r ec o n c e n -
trated mostly within the interval of the first few bins,
and as the rank ratios increase, corresponding
frequencies all take a general trend of declination. In
other words, the proposed approach is capable of rank-
ing domains known as associated with some disease
phenotypes among the top of the candidates.
We then assess the performance of the proposed
approach using the three criteria (mean rank ratio, pre-
cision, and AUC score) and summarize the results in
Table 1. First, we can see from these results that the
domainRBF approach can successfully recover the asso-
ciations between protein domains and human disease
phenotypes. For example, in the cross-validation for ran-
dom controls, the precisionsa r eg r e a t e rt h a n2 6 % ,t h e
mean rank ratios are less than 12%, and the AUC scores
are greater than 88%. In the cross-validation for linkage
intervals, the precisions are greater than 23%, the mean
rank ratios are less than 12%, and the AUC scores are
g r e a t e rt h a n8 9 % .I nt h ec r o ss-validation for genome-
wide scan, the precisions are greater than 5%, the mean
rank ratios are less than 12%, and the AUC scores are
greater than 88%. We therefore conclude that the
domainRBF approach is effective in the identification of
domains that are associated with human disease
phenotypes.
Second, we conjecture from these results that the dif-
fusion kernel measure is slightly better than the shortest
path measure with Gaussian kernel, because the mean
rank ratios obtained using the diffusion kernel are in
general smaller, and the precisions and AUC scores are
in general larger, than those obtained using the shortest
path with Gaussian kernel. This phenomenon might be
explained by the fact that diffusion kernel is a global
network-distance measure. As such, the distance
between two domains not only depends on the relative
location of the candidate domain to all other domains
Figure 2 Bayes factors of the original and permuted data. “original”, “permuted PPS”, “permuted seed”, “random seed”,a n d“permuted DDI”
denote the results obtained using the original data, permuted phenotype similarity profile, permuted domain-disease associations, randomly
selected seed domains, and permuted domain-domain interaction network, respectively. The small domain-domain interaction network
composed of the PDB part of the DOMINE database and the diffusion kernel are used to obtain the results.
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Page 7 of 21(as the shortest path with Gaussian kernel does), but
also relies on the graph structure of the entire network.
Thus, for interaction networks with different graph
structure, two nodes with the same shortest path dis-
tance usually have different diffusion kernel distance,
and it is possible that this difference makes the diffusion
kernel distance more reasonable and precise in the
description of similarities between two domains in the
interaction network. This point has also been explicitly
illustrated in literature [29].
Third, we conjecture from these results that the
domainRBF approach with some proper defined priors
can achieve higher performance than the non-Bayesian
linear regression method. We compare the perfor-
mance of the (Bayesian) domainRBF approach with the
(non-Bayesian) ordinary linear regression method
through the three large-scale leave-one-out cross-vali-
dation experiments, and we also list the results in
Table 1. Although both approaches can successfully
recover the associations between protein domains and
Figure 3 Histograms of rank ratios for domains known to be associated with diseases. (A) Results for shortest path with Gaussian kernel,
against random controls. (B) Results for shortest path with Gaussian kernel, against linkage intervals. (C) Results for shortest path with Gaussian
kernel, against genome-wide scan. (D) Results for diffusion kernel, against random controls. (E) Results for diffusion kernel, against linkage
intervals. (F) Results for diffusion kernels, against genome-wide scan. The small domain-domain interaction network composed of the PDB part of
the DOMINE database and the diffusion kernel are used to obtain the results.
Table 1 Results of leave-one-out cross-validation experiments on the small network.
Random Control (%) Linkage Interval (%) Genome-wide Scan(%)
R
2 BF R
2 BF R
2 BF
Precision SG 26.11 (0.66) 26.56 (0.85) 21.69 23.79 6.29 5.25
DK 26.25 (0.63) 28.67 (0.72) 19.60 31.20 7.13 5.53
Mean Rank Ratio SG 17.31 (0.11) 11.99 (0.05) 18.24 11.19 16.49 11.17
DK 17.82 (0.13) 10.75 (0.09) 19.09 9.73 17.03 9.91
AUC SG 83.51 (0.10) 88.80 (0.05) 82.81 89.94 83.60 88.85
DK 83.01 (0.12) 90.04 (0.11) 81.95 90.18 83.06 90.11
The small network indicates the domain-domain interaction network that is composed of the PDB part of the DOMINE database. R
2 denotes the ordinary non-
Bayesian linear regression approach (using R-square as scores for candidate domains). BF denotes the domainRBF approach (using Bayes factors as scores for
candidate domains). SG denotes shortest path with Gaussian kernel. DK denotes diffusion kernel. Results for random controls are mean (standard deviation) of 10
validation runs.
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Page 8 of 21human disease phenotypes, the results show that the
domainRBF approach can achieve better performance
than the ordinary linear regression approach in most
cases. For example, in all three cross-validation experi-
ments, the domainRBF approach can achieve higher
precisions (with only two exceptions for genome-wide
scan), smaller mean rank ratios (for at least 5.32%),
and larger AUC scores (for at least 3.19%). When look-
ing at the ROC curves (Figure 4), we see that the curve
of the domainRBF approach climbs much faster
towards the upper left corner of the plot than does
that of the ordinary linear regression approach, sug-
gesting that the Bayesian domainRBF approach is
superior to the non-Bayesian ordinary linear regression
method.
Robustness of the DomainRBF approach
Effects of network interactions
The above validation results suggest that the domainRBF
approach can successfully prioritize candidate domains
and put the domain that is truly associated with the
query disease phenotype at the top of the candidates.
However, it is still necessary to determine whether the
correct prioritization of disease domains is due to the
connectivity information that includes in the domain-
domain interactions, domain-phenotype associations, and
phenotype-phenotype similarities. To accomplish this, we
artificially destroy informative interactions in the above
three networks and see what performances will turn out.
It is expected that both the mean rank ratios and the
AUC scores will be around 50%, together with very low
Figure 4 ROC curves of the leave-one-out cross-validation experiments. (A) Results for random controls. (B) Results for linkage intervals. (C)
Results for genome-wide scan. BF: the domainRBF approach (using Bayes factors as scores for candidate domains). R
2: the ordinary non-Bayesian
linear regression approach (using R-square as scores for candidate domains). SG: shortest path with Gaussian kernel. DK: diffusion kernel.
Numbers in the parentheses are AUC scores of the corresponding ROC curves. The small domain-domain interaction network composed of the
PDB part of the DOMINE database is used to obtain the results.
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Page 9 of 21precisions. With this understanding, we perform three
permutation experiments: 1) shuffling interactions
among domains while fixing the node degree (number of
direct neighbours) distribution of the entire interaction
network, 2) shuffling interactions among domain-pheno-
type associations while fixing the number of associated
domains for each of the phenotypes, and 3) shuffling the
phenotype-phenotype similarity while fixing the distribu-
tion of phenotype similarities, respectively. Then we
repeat the leave-one-out cross-validation experiments
using the shuffled networks, which contain no informa-
tive interactions among domains, among domain and
phenotypes, or among phenotypes, respectively. As
shown in Figure 5, the results obtained are generally
consistent with our expectation in that AUC scores are
all around 50%. We therefore conclude that the success-
ful prioritization of candidate domains is indeed due to
the informative interactions among domains that are
included in the domain-domain interaction network.
Effects of different domain-domain interaction networks
We notice that the two compiled domain-domain inter-
action networks have different properties. For example,
the average degree of the smaller network that includes
only PDB entries is 2.32, while that of the larger net-
work that includes predicted interactions from both
DOMINE and InterDom is 17.77. It is possible that
many predicted interactions may actually be noise and
thus negatively affect the prioritization of disease
Figure 5 ROC curves of the leave-one-out cross-validation experiments on shuffled data. (A) Results for random controls with domain-
domain interactions shuffled. (B) Results for linkage intervals with domain-domain interactions shuffled. (C) Results for genome-wide scan with
domain-domain interactions shuffled. (D) Results for random controls with known domain-phenotype associations shuffled. (E) Results for linkage
intervals with known domain-phenotype associations shuffled. (F) Results for genome-wide scan with known domain-phenotype associations
shuffled. (G) Results for random controls with phenotype similarity profiles shuffled. (H) Results for linkage intervals with phenotype similarity
profiles shuffled. (I) Results for genome-wide scan with phenotype similarity profiles shuffled. The small domain-domain interaction network
composed of the PDB part of the DOMINE database and the diffusion kernel are used to obtain the results.
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Page 10 of 21domains. Hence, it is necessary to validate the robust-
ness of the proposed approaches to the underlying
domain-domain interactions. For this purpose, we
implement the same validation process based on the
large compiled domain-domain interaction network that
is composed of all interactions in the DOMINE database
and high-confidence interactions in the InterDom data-
base. Results are presented in Table 2, from which we
can see that the performances of the domainRBF
approach using the large domain-domain interaction
network that includes the entire DOMINE database and
the high-confidence interactions in the InterDom data-
base are generally somewhat inferior to those using the
P D Bp a r to ft h eD O M I N Ed a t a b a s e .F o ri n s t a n c e ,w h e n
using the domainRBF approach,t h ed i s p a r i t yo fp r e c i -
sions, mean rank ratios and AUCs are all within the
scope of 10 percent. We then conjecture from these
results that the proposed domainRBF approach is quite
robust to the possible noise in the domain-domain
interaction network.
Effects of parameters in the distance measures
We further notice that the parameter b in the shortest
path measure with Gaussian kernel and the parameter g
in the diffusion kernel are free parameters that need to
be pre-determined (see Materials and Methods for
details). In the above cross-validation experiments we
set these parameters as 1 and 0.05, respectively, for sim-
plicity. However, it is necessary to show whether the
prioritization methods are sensitive to these parameters.
For this purpose, we select several values across the
range of these parameters, perform the cross-validation
experiments, and see how the results change accord-
ingly. We take the prioritization results using the
domainRBF approach against random controls (in Table
1) as an example to illustrate the influence of b.S i n c e
this parameter ranges from 0 to +∞,w ep e r f o r mag r i d
search of this parameter by changing it from 0.1 to 10
with step 0.1 and see the effect, as reflected in the
change of precision, mean rank ratio, and AUC score as
shown in Figure 6(A). From the curve we can see that
when b changes from 0.1 to 1, there is an obvious
upward climb for the three criteria, while after the point
b = 1.0 (precision = 26.56%, mean rank ratio = 11.99%,
and AUC score = 88.80%), the values in the curve
becomes fairly stable. Even so, we find that the peak
performance is obtained at b = 3.7 (precision = 28.89%,
mean rank ratio = 10.67%, and AUC score = 90.20%),
and the worst performance is obtained at b = 0.1 (preci-
sion = 18.01%, mean rank ratio = 19.23%, and AUC
s c o r e=8 1 . 6 3 % ) .F r o mt h e s er e s u l t s ,w ec o n c l u d et h a t
the prioritization methods are not sensitive to this free
parameter when b is greater than 1. Similarly, we find
that the prioritization methods are not sensitive to the
free parameter g when it is smaller than 0.15 (data not
shown). The corresponding changes in precision, mean
rank ratio, and AUC score are shown in Figure 6(B).
We find that the peak performance is obtained at g =
0.03 (precision = 29.55%, mean rank ratio = 10.61%, and
AUC score = 90.16%), and the worst performance is
obtained at g = 0.93 (precision = 24.86%, mean rank
ratio = 13.34%, and AUC score = 87.46%). From the
results, we can see that the proposed approach is quite
robust when b in the shortest path with Gaussian kernel
is greater than 1 or when g in the diffusion kernel is
smaller than 0.15.
Effects of parameters in the domainRBF approach
Besides the two parameters in the distance measures,
there are also four parameters in the domainRBF
approach that need to be pre-determined, namely μ0,
s1
2, n0,a n ds0
2, all of which are included in the priors
of the domainRBF approach (see Materials and Methods
for details). In the real implementation we set μ0 = 0, n0
=0 ,a n ds0
2 = 0, for the reason explained in the litera-
ture [44], and we set s1
2 = 1, for simplicity. Therefore,
we only need to test the robustness of the approach
when different values of s1
2 are used. To achieve this
objective, we set s1
2 as 0.001, 0.01, 0.1, 1, 10, and 100,
respectively, and we apply the approach to the same
cross validation process. We list the results in Table 3,
which shows that when s1
2 is smaller than 1, the
Table 2 Results of leave-one-out cross-validation experiments on the large network.
Random Control (%) Linkage Interval (%) Genome-wide Scan (%)
R
2 BF R
2 BF R
2 BF
Precision SG 14.24 (0.37) 18.64 (0.66) 18.54 21.23 2.17 2.35
DK 16.80 (0.36) 22.32 (0.60) 17.36 27.56 2.42 3.47
Mean Rank Ratio SG 27.27 (0.07) 19.59 (0.09) 21.89 18.07 26.53 18.79
DK 26.07 (0.11) 14.96 (0.07) 20.21 14.12 25.34 14.11
AUC SG 73.41 (0.07) 81.15 (0.09) 78.57 81.76 73.38 81.09
DK 74.61 (0.11) 85.82 (0.07) 82.36 86.68 74.55 85.72
The large network indicates the domain-domain interaction network that is composed of the entire DOMINE database and high-confidence interactions in the
InterDom database. R
2 denotes the ordinary non-Bayesian linear regression approach (using R-square as scores for candidate domains). BF denotes the
domainRBF approach (using Bayes factors as scores for candidate domains). SG denotes shortest path with Gaussian kernel. DK denotes diffusion kernel. Results
for random controls are mean (standard deviation) of 10 validation runs.
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Page 11 of 21domainRBF approach is quite robust to the change of
s1
2, with the change of precision within 1.12%, change
of mean rank ratios within 0.53%, and change of AUC
scores within 0.54%. On the other hand, when s1
2 is lar-
ger than 1, the decrease in performances becomes
slightly conspicuous, but remains within the scope of
3.04% for precisions, 2.22% for mean rank ratios and
1.77% for AUC scores. Hence we can see that our
domainRBF approach is generally robust to the change
of parameters.
Effects of seed domain-disease associations
In order to test the influence of the size of seed, or
known associations on the prioritization results, we
select at random 100%, 90%, 80%, 70%, 60%, and 50% of
the original seed associations, respectively, and we
repeat the leave-one-out validation processes. We only
calculate the performance using the domainRBF
approach based on diffusion kernel measure, and we
choose the PDB part of the DOMINE database as the
domain-domain interaction network. Results show that
Figure 6 Effects of parameters on distance measures. (A) Influence of b (from 0.1 to 10 with step 0.1) on shortest path with Gaussian kernel.
(B) Influence of g (from 0.01 to 1 with step 0.01) on diffusion kernel. The small domain-domain interaction network composed of the PDB part
of the DOMINE database is used to obtain the results.
Table 3 Effects of parameters based on leave-one-out cross-validation experiments.
Criteria s1
2 Random Control (%) Linkage Interval (%) Genome-wide Scan (%)
Precision 0.001 28.87 (0.70) 31.49 4.41
0.01 29.02 (1.17) 31.77 4.78
0.1 29.39 (0.60) 31.36 5.07
1 28.67 (0.72) 31.20 5.53
10 27.76 (0.62) 29.73 5.35
100 28.59 (1.18) 28.16 5.35
Mean Rank Ratio 0.001 10.23 (0.07) 9.83 9.38
0.01 10.25 (0.11) 9.98 9.41
0.1 10.41 (0.07) 9.49 9.54
1 10.75 (0.09) 9.73 9.91
10 11.14 (0.10) 10.92 10.27
100 12.08 (0.10) 11.95 11.24
AUC 0.001 90.58 (0.10) 90.14 90.55
0.01 90.56 (0.14) 90.40 90.61
0.1 90.40 (0.10) 90.22 90.40
1 90.04 (0.11) 90.18 90.11
10 89.69 (0.10) 89.23 89.86
100 88.74 (0.14) 88.41 88.98
The small domain-domain interaction network composed of the PDB part of the DOMINE database and the diffusion kernel are used to obtain the results. Results
for random controls are mean (standard deviation) of 10 validation runs.
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Page 12 of 21with the percentage of seed associations decreases from
100% to 50%, performance also slightly decreases in
terms of precision, mean rank ratio and AUC score,
despite some exceptions (see Table 4). For example, in
the cross-validation for random controls, the changes of
precisions are no more than 2.99%, the changes of mean
rank ratios are no more than 2.72%, and the changes of
AUC scores are no more than 2.73%. In the cross-vali-
dation for linkage intervals, the changes of precisions
are no more than 2.73%, the changes of mean rank
ratios are no more than 0.75%, and the changes of AUC
scores are no more than 0.78%. In the cross-validation
for genome-wide scan, the changes of precisions are no
more than 1.95%, the changes of mean rank ratios are
no more than 1.04%, and the changes of AUC scores
are no more than 0.95%. From these results, we con-
clude that the prioritization methods are not sensitive to
the size of seed associations in our problem.
In order to study how known domain-disease associa-
tions for other diseases contribute to the inference of
domains that are associated with the query disease, we
keep 10%, 20%, 30%, 40%, and 50% disease phenotypes
that have the highest similarity scores to the query dis-
ease, respectively, and we repeat the leave-one-out vali-
dation processes, using the diffusion kernel measure and
the small domain-domain interaction network that is
composed of the PDB part of the DOMINE database.
Results (Table 5) show that our method is robust in this
experiment, in the sense that the values of the three
evaluation criteria do not change significantly. For
example, in the cross-validation for random controls,
the changes of precisions are no more than 6.64%, the
changes of mean rank ratios are no more than 1.15%,
and the changes of AUC scores are no more than
1.20%. However, we also notice that the performance of
our approach tends to drop when more phenotypes
with lower similarity scores are included. For example,
in the experiment, our approach achieves the highest
performance when keeping only 10% phenotypes which
have the highest similarity scores to the query pheno-
type and the lowest performance when keeping 50% of
the most similar phenotypes, although the drop in per-
formance is small. We also repeat the above analysis
using the large domain-domain interaction network that
i n c l u d e st h ee n t i r eD O M I N Ed a t a b a s ea n dt h eh i g h -
confidence part of the InterDom database, and we
obtain similar results [Additional file 2: Supplemental
Table S1]. From these results, we conclude that seed
domain-disease associations in which the diseases have
high phenotype similarity scores with the query disease
have main contributions in the prioritization procedure.
Ab initio inference of domain-disease and gene-disease
associations
A b o v ew eh a v eu s e ds e v e r a ll a r g es c a l el e a v e - o n e - o u t
cross-validation experiments to evaluate the perfor-
mance and robustness of the proposed domainRBF
approach. However, it might be argued that a disease
may be associated with more than one domain and that,
consequently, the inclusion of domains already known
to be associated with the query disease in the calculation
of the domain proximity profile may ease the identifica-
tion of novel associations. Following this line of reason-
ing, we demonstrate the capability of the proposed
domainRBF approach in the prediction of novel associa-
tions for query diseasesby performing the following ab
Table 4 Effects of seed domain-disease associations based on leave-one-out cross-validation experiments.
Criteria Cutoff Random Control (%) Linkage Interval (%) Genome-wide Scan (%)
Precision 90% 28.28 (0.42) 33.45 (1.57) 5.34 (0.33)
80% 27.42 (0.76) 32.06 (1.44) 4.79 (0.47)
70% 27.43 (1.06) 29.59 (0.93) 3.97 (0.74)
60% 25.68 (1.04) 30.11 (1.10) 3.58 (0.58)
50% 25.85 (0.73) 28.47 (0.89) 5.35 (1.22)
Mean Rank Ratio 90% 10.90 (0.78) 8.98 (0.64) 10.16 (0.81)
80% 11.23 (0.84) 9.37 (0.92) 10.38 (1.02)
70% 11.68 (1.21) 10.09 (1.05) 10.61 (0.69)
60% 12.37 (0.97) 9.21 (1.01) 10.76 (0.80)
50% 13.47 (0.55) 9.72 (0.98) 10.95 (0.78)
AUC 90% 89.92 (0.30) 90.83 (0.58) 89.87 (0.61)
80% 89.60 (0.22) 90.26 (0.43) 89.66 (0.29)
70% 89.15 (0.17) 89.40 (0.64) 89.46 (0.48)
60% 88.48 (0.59) 90.01 (0.51) 89.32 (0.34)
50% 87.31 (0.28) 89.89 (0.46) 89.16 (0.75)
The small domain-domain interaction network composed of the PDB part of the DOMINE database and the diffusion kernel are used to obtain the results. Results
for random controls are mean (standard deviation) of 10 validation runs.
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Page 13 of 21initio inference experiments. For each query disease, we
calculate domain proximity profiles with the exclusion
of all domains that are known to be associated with the
disease (i.e., as if genetic bases of the disease were com-
pletely unknown), apply the domainRBF method to
score candidate domains, and then prioritize the candi-
dates. We again perform random control, linkage inter-
val, and genome-wide validation experiments and
evaluate the performance of our approach in terms of
precision, mean rank ratio, and AUC scores. We per-
form this ab initio inference using the large network
that is composed of entire interactions in DOMINE and
high-confidence interactions in InterDom (with diffusion
kernel), and we summarize the results in Table 6.
In comparison with the results in Table 2, we find that
the performance of the domainRBF approach slightly
drops (less than 4%). For example, for the random con-
trol validation, the precision is almost the same, the
mean rank ratio drops from 14.96% to 17.34%, and the
AUC score from 85.82% to 83.43%. For the linkage
interval validation, the precision drops from 27.56% to
24.39%, the mean rank ratio from 14.12% to 17.07%,
and the AUC score from 86.68% to 84.62%. For the gen-
ome-wide validation, the precision even increases
slightly from 3.47% to 3.90%, while the mean rank ratio
drops from 14.11% to 16.45% and the AUC score from
85.72% to 83.27%. In other words, for a query disease of
interest, our approach is capable of inferring novel asso-
ciations between domains and the disease without prior
knowledge about genetic bases of the disease. This char-
acteristic of our approach is of great importance,
because the genetic bases for about half of the diseases
in the OMIM database are still unknown [47].
We also study the contribution of seed domain-disease
associations by keeping a fraction of disease phenotypes
that have the highest similarity scores to the query dis-
ease and repeating ab initio prediction experiments. We
observe from the results [Additional file 2: Supplemental
Tables 2 and 3] that seed domain-disease associations in
which the diseases have high phenotype similarity scores
with the query disease have main contributions in the
prioritization procedure. We further study whether the
ab initio prediction tends to give higher ranks to
domains that occur more frequently in human proteins.
We merge the frequency of occurrence of domains in
all human proteins into 11 bins (0-10, 11-20, 21-30, 31-
40. 41-50, 51-60, 61-70, 71-80, 81-90. 91-100, 101 and
above), and we look at how ranks of domains that are
known to be associated with diseases distribute in differ-
ent bins. From the results [Additional file 1: Supplemen-
tal Figure S2], we see that the median of mean ranks of
such domains do not show much change for different
bins, indicating that our method is not biased towards
common domains.
Table 5 Contributions of seed domain-disease associations based on leave-one-out cross-validation experiments.
Criteria Cutoff Random Control (%) Linkage Interval (%) Genome-wide Scan (%)
Precision 10% 37.82 (0.72) 42.29 8.16
20% 34.55 (1.03) 38.39 8.63
30% 32.85 (0.77) 37.52 7.79
40% 32.78 (0.97) 36.98 7.79
50% 31.18 (0.62) 34.50 6.16
Mean Rank Ratio 10% 8.83 (0.06) 7.87 7.96
20% 8.80 (0.07) 7.92 7.95
30% 9.23 (0.03) 8.47 8.33
40% 9.64 (0.07) 8.61 8.74
50% 9.98 (0.06) 8.86 9.09
AUC 10% 92.14 (0.12) 94.08 91.75
20% 92.16 (0.10) 93.91 91.83
30% 91.71 (0.10) 93.46 91.42
40% 91.33 (0.08) 92.63 91.08
50% 90.94 (0.06) 92.30 90.66
The small domain-domain interaction network composed of the PDB part of the DOMINE database and the diffusion kernel are used to obtain the results. Results
for random controls are mean (standard deviation) of 10 validation runs.
Table 6 Ab initio inference of domain-disease associations.
Random Control (%) Linkage Interval (%) Genome-wide Scan (%)
Precision 22.11 (0.45) 24.39 3.90
Mean Rank Ratio 17.34 (0.07) 17.07 16.45
AUC 83.43 (0.07) 84.62 83.27
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Page 14 of 21Inspired by the success of ab initio inference of
domains and diseases, we further propose the following
application of the proposed domainRBF approach in the
inference of genes that are associated with diseases, by
combining predicted domain-disease associations and
known domain-protein relations. As shown in Figure 7,
given a query disease and a gene whose products (pro-
teins) are usually composed of several protein domains,
we look at corresponding Bayes factors of these domains
and define an association score that measures the
strength of association between the gene and the disease
as the maximum among these Bayes factors. Then,
given a set of candidate genes, we are able to obtain
association scores for the genes and further rank the
genes according to their scores.
We validate our gene prioritization approach using
known gene-disease associations extracted from the Bio-
Mart database [48,49]. After ruling out diseases that do
not exist in our phenotype similarity network and genes
whose products do not have domain annotation, we
obtain 2,847 associations between 1,737 genes and 1,875
diseases. We then prioritize each of these genes that are
known to be associated with some diseases (disease
genes) against a total of 14,944 genes whose products
have domain annotations. Results show that in 207 out
of the 2,847 associations, the known disease genes rank
first in the candidate list of 14,944 genes, obtaining a
precision of 7.27%, as well as a fold enrichment of 1,087
(It should be noted that fold enrichment is defined in
existing literature [32] as follows: for a method that is
able to rank known disease genes among the top a%o f
all candidates in b% validation runs, the fold enrichment
is b/a on average). In other words, our domainRBF
approach can also be effectively used as an intermediate
step to infer associations between genes and diseases.
Genome-wide evidence of associations between domains
and common human diseases
The identification of susceptible single nucleotide poly-
morphisms (SNPs) conferring risk for common human
diseases is one of the main tasks of genome-wide asso-
ciation studies (GWAS). Since the study that identified
the association of complement factor H (CFH) with age-
related macular degeneration (AMD) in 2005, over 450
GWAS have been performed and more than 2,000 sus-
ceptible SNPs or genetic loci have been reported [50].
With these resources, it is of interest to to determine
the extent to which the genome-wide ab initio inference
of associations between domains and diseases are con-
sistent with these GWAS results.
Given a disease of interest, we collect from SNPedia
[51,52] or other relevant literatures a list of reported
susceptible SNPs, and we see how many of these SNPs
appear within 5 Mbp of the domains that are ranked in
the top 10 in our genome-wide ab initio inference,
which uses all domains in the domain-domain interac-
tion network as candidates. We further implement the
following permutation test to check whether the number
Figure 7 Scheme of inferring gene-disease associations from domain-disease associations.
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Page 15 of 21of such susceptible SNPs is significantly enriched within
these regions, as
1. Count the number of reported SNPs that appear
within 5 Mbp of domains that are ranked among the
top 10 in the genome-wide ab initio inference.
Record this number as N0.
2. For the i-th permutation, select 10 domains at
random from all domains in the genome-wide ab
initio inference. Count the number of reported SNPs
that appear within 5 Mbp of these domains. Record
this number as Ni.
3. Repeat the above random selection M times (M =
10,000 in our study). Count the number of times
that Ni (i = 1,...,N) is greater than or equal to N0.
Record this number as m.
4. Calculate a p-value as p = m/M.
The null hypothesis in the above permutation test is
that the number of the reported susceptible SNPs within
5M b pr e g i o n so ft h eh i g hr a n k i n gd o m a i n s( t o p1 0 )i s
not different from that of randomly selected domains.
Therefore, a small p-value indicates that the reported
susceptible SNPs tend to be closer to the high ranking
domains. In other words, high ranking domains are
more likely to be associated with the disease under
investigation.
We then select four disease examples (Type 1 dia-
betes, Type 2 diabetes, Crohn’s disease, and Breast can-
cer), apply the above permutation test method to these
diseases, and analyze the results in detail. We choose
these four diseases because they are common and have
GWAS results available. It has been shown that diabetes
had affected 2.8% of the population worldwide by 2000
[53], with type 2 diabetes as the most common form of
this disease [54]. It is also known that Crohn’sd i s e a s e
affects 0.2% to 0.1% people within the UK [55], and that
breast cancer is the most common type of non-skin can-
cer in women and the fifth most common cause of can-
cer death [56,57].
Type 1 Diabetes
Type 1 diabetes, formerly called juvenile diabetes or
insulin-dependent diabetes, is a condition in which pan-
creatic b cell destruction usually leads to absolute insu-
lin deficiency [58]. The genetic susceptibility of Type 1
diabetes is strongly associated with HLA-DQ and DR on
chromosome 6, but genetic factors on other chromo-
somes such as the insulin gene on chromosome 11 and
the cytotoxic T-lymphocyte antigen gene on chromo-
some 2 may modulate disease risk [59]. In our study, we
compile from SNPedia 48 reported susceptible SNPs,
and 25 of them are found to be within 5Mbp regions of
6 domains (i.e., NACHT, Recep_L_domain, Collagen,
H N F - 1 A _ C ,C A R D ,a n dF G F )t h a ta r er a n k e da m o n g
the top 10. We present the detailed list of these domains
and SNPs [Additional file 2: Supplemental Table S4]. In
summary, we observe 3 times that a susceptible SNP
locates inside a domain (once in each of Recep_L_do-
main, Collagen, and HNF-1A_C, respectively), 15 times
that a susceptible SNP locates within 1 Mbp upstream
or downstream of a domain, and 44 times that a suscep-
tible SNP locates within 5 Mbp region of a domain. The
permutation test, as described above, yields a p-value of
0.0313, which is smaller than 0.05. From these results
we conjecture that domains ranked among the top 10
do, indeed, tend to be closer to, or even include, known
susceptible SNPs for this disease.
In addition, we also examine the 4 domains that are
not close to susceptible SNPs reported by GWAS. For
domain HNF-1B_C (PF04812), we notice that Urham-
mer et al. [60] have pointed out that mutations and
polymorphisms in HNF-1 cause the type 3 form of
maturity-onset diabetes of the young (MODY3), and for
domain HNF-1_N (PF04814), mutations and the com-
mon polymorphism Ala/Val in position 98 of HNF-1
also cause MODY3. It is known that MODY3 is a kind
of monogenic diabetes, which is different from type 1
diabetes that involves more complex combinations of
causes involving multiple genes and environmental fac-
tors (i.e., polygenic). However, most commonly MODY3
acts like a very mild version of type 1 diabetes, with
continued partial insulin production and normal insulin
sensitivity [61]. Therefore, domain HNF-1B_C
(PF04812) and domain HNF-1_N (PF04814), which are
highly ranked in terms of our approach, may also be
closer to, even include, known susceptible SNPs for this
disease.
Type 2 Diabetes
Type 2 diabetes, formerly called adult-onset diabetes or
noninsulin-dependent diabetes, is the most common
form of diabetes. It usually begins with insulin resis-
tance, a condition in which fat, muscle, and liver cells
do not use insulin properly [62]. Numerous SNPs have
been associated with (slightly) increased risk for type-2
diabetes [63,64], but they only marginally improve the
odds of predicting whether an individual will get type-2
diabetes based on the traditional clinical characteristics
combining age, sex and weight [65]. In our study, we
compile from SNPedia and reference [64] a total of 53
reported susceptible SNPs, and 24 of them are found to
be within 5 Mbp regions of 7 domains (i.e., HNF-1B_C,
IF_tail, Sulfatase, Collagen, Alk_phosphatase, Pkinase_-
Tyr, and FGF) that are ranked among top 10. We pre-
sent the detailed list of these domains and SNPs
[Additional file 2: Supplemental Table S5]. In summary,
we observe 47 times that a susceptible SNP locates
within 1 Mbp upstream or downstream of a domain,
and 102 times that a susceptible SNP locates within 5
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p-value of 0.0363, which is smaller than 0.05. From
these results we conjecture that domains ranked among
the top 10 do, indeed, tend to be closer to known sus-
ceptible SNPs for this disease.
In addition, we also examine the 3 domains that are
not close to susceptible SNPs reported by GWAS. We
notice that both domains HNF-1A_C (PF04813) and
HNF-1_N (PF04814) contain mutations that may cause
the type 3 form of maturity-onset diabetes of the young
(MODY3), as pointed out by Urhammer et al. [60].
Although type 2 diabetes may share some characteristics
in common with MODY3, no direct evidence has yet
been found to demonstrate that these two domains
cause type 2 diabetes.
Crohn’s Disease
Crohn’s disease, a chronic inflammatory disorder of the
gastrointestinal tract, is thought to result from the com-
bination of effect of environmental factors and genetic
predisposition [66,67]. Recently, genome-wide associa-
tion studies have made notable progress in the study of
this disease, with the number of confirmed associated
loci increasing from two to more than ten [68,69]. In
our study, we compile from SNPedia 36 reported sus-
ceptible SNPs, and 29 of them are found to be within 5
Mbp regions of 8 domains (i.e., Sulfatase, NACHT, Col-
lagen, Crystall, Pkinase_Tyr, CARD, Gla, and Hor-
mone_1) that are ranked among top 10. We present the
detailed list of these domains and SNPs [Additional file
2: Supplemental Table S6]. In summary, we observe 5
times that a susceptible SNP locates inside a domain (3
times in NACHT and 2 times in Pkinase_Tyr), 21 times
that a susceptible SNP locates within 1 Mbp upstream
or downstream of a domain, and 49 times that a suscep-
tible SNP locates within 5 Mbp region of a domain. The
permutation test yields a p-value of 0.0029, which is far
smaller than 0.05. From these results we conjecture that
domains ranked among the top 10 do, indeed, tend to
be closer to, or even include, known susceptible SNPs
for this disease.
Breast Cancer
Breast cancer, the most common malignancy in women
in the Western world [70], exhibits a characteristic of
familial clustering [70,71]. Although little is known cur-
rently to explain the familial clustering of breast cancer,
a large amount of susceptible genes and SNPs of this
disease have been recently reported, including the well-
known high breast cancer risk in BRCA1 and BRCA2
mutation carriers as well as the risk for breast cancer in
certain rare syndromes caused by mutations in TP53,
STK11, PTEN, CDH1, NF1 or NBN [70]. In our study,
we compile from SNPedia 60 reported susceptible SNPs,
and 38 of them are found to be within 5 Mbp regions
of 7 domains (i.e., Sulfatase, Pkinase_Tyr, Crystall, FGF,
Collagen, NACHT, and Recep_L_domain) that are
ranked among the top 10. We present the detailed list
of these domains and SNPs [Additional file 2: Supple-
mental Table S7]. In summary, we observe 6 times that
as u s c e p t i b l eS N Pl o c a t e si n s i d ead o m a i n( a l li nP k i n a -
se_Tyr), 21 times that a susceptible SNP locates within
1 Mbp upstream or downstream of a domain, and 80
times that a susceptible SNP locates within 5 Mbp
region of a domain. The permutation test yields a p-
value of 0.0159, which is smaller than 0.05. From these
results we conjecture that domains ranked among the
top 10 do, indeed, tend to be closer to, or even include,
known susceptible SNPs for this disease.
Contributions of seed domain-disease associations in the
analysis of the four diseases
For each of the four diseases examples, we further eval-
uate the contribution of seed domain-disease associa-
tions by keeping 10%, 20%, 30%, 40%, and 50% disease
phenotypes that have the highest similarity scores to the
query disease, obtaining a rank list of all domains, and
then using the permutation test to check whether the
number of known susceptible SN P si ss t i l ls i g n i f i c a n t l y
enriched around the top ranking domains. As shown in
[Additional file 2: Supplemental Table S8], we find that
all resulting p-values are smaller than 0.05, and are also
numerically close to those obtained using all pheno-
types. We therefore conjecture that our approach is
robust to the seed domain-disease associations in the
inference for these disease examples.
A predicted landscape of domain-disease associations
With the above validation results demonstrating the
possibility of recovering the associations between pro-
tein domains and disease phenotypes, we further apply
the domainRBF approach to all available protein
domains and human disease phenotypes and predict a
genome-wide landscape of the associations between pro-
tein domains and human disease phenotypes. There are
a total of 5,080 phenotypes in the phenotype similarity
network and 5,490 protein domains in the domain-
domain interaction network (the union of the entire
DOMINE and InterDom network). For each phenotype,
we perform a prioritization of all domains with the use
of the domainRBF approach (using the diffusion kernel
measure). The prioritization results, together with a
freely accessible web interface, are provided at http://
bioinfo.au.tsinghua.edu.cn/domainRBF/domain. All
domains on the webpage are linked to the DOMINE
database and the InterDom database, from which further
information can be obtained.
On the basis of the above prioritization results, we
aggregate the Bayes factors between all the 5,490
domains and 1,145 phenotypes, and obtain a matrix of
altogether 6,286,050 elements. Here we first make a log
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ment clustering while removing the rows in which the
values are all smaller than 0.1. Since phenotypes clus-
tered together generally have similar molecular basis, or
share significant genetic overlaps [32], we implement a
two-way hierarchical clustering [72], to identify interest-
ing areas where large values of Bayes factors are highly
enriched. The clustering result is demonstrated in the
form of a heat map, as shown in Figure 8(A). We then
manually inspect and annotate each of the phenotype
clusters with one of the 22 disorder classes based on the
physiological system affected [73]. Through clustering,
many highly scored blocks or regions are formed in the
heat map, each of which represents a set of functionally
related domains implicated in a set of genetically over-
lapping phenotypes [32]. Specifically, we take the region
in the pink circle as an example, which is enlarged in
Figure 8(B). Phenotypes in the region selected are
enriched with diseases related to the muscle system, and
domains are also conjectured to share similar functions
with adjacent domains in the same region.
We further apply the above prioritization method to
all human disease phenotypes and obtain a landscape of
gene-phenotype associations that include 5,080 disease
phenotypes and 14,944 human genes. The prioritization
results, together with a freely accessible web interface,
are provided at http://bioinfo.au.tsinghua.edu.cn/
domainRBF/gene/. All genes on the webpage are linked
to the Ensembl database [74], from which further infor-
mation can be obtained.
Discussion and Conclusions
In this paper, we studied the problem of identifying
domains that are associated with human inherited dis-
eases under a prioritization framework. We proposed an
approach called domainRBF from the perspective of
Bayesian regression, verified its superior performance
through three large-scale cross-validation experiments,
and demonstrated the robustness of this approach via a
series of permutation tests. We further proposed to per-
form ab initio inference of domain-disease associations
and gene-disease associations. Finally, we calculated a
landscape between 5,490 protein domains and 5,080 dis-
ease phenotypes.
In comparison with previous studies that rely on phe-
notype similarity and protein-protein interaction data to
infer gene-disease associations [32], our approach can
achieve higher resolution in pinpointing susceptibility
functional units in the genome, essentially because a
domain is only a fraction of a protein and is typically
small in size (ranging between 40 and 700 residues [75]
with an average of approximately 100 residues [76]).
Moreover, as demonstrated in the Results section, our
approach can also be used as an intermediate step in
the inference of gene-disease associations.
However, our method has the following limitations.
First, our method can only be applied to diseases that
are included in phenotype similarity data and domains
that are included in domain interaction data. In the case
of phenotype similarity, a possible solution would
involve the development of a visualization and annota-
tion system such as the one in [77] that can associate a
new disease to a standard vocabulary and then calculate
similarities for the new disease. In the case of domain
interaction data, a possible solution would involve the
development of effective computational methods to pre-
dict domain-domain interactions.
Second, our method currently only considers conju-
gate priors in the Bayesian regression model. Although
such formulation results in analytic solutions and thus
alleviates the computational burden in the calculation of
Bayes factors, it is known that the specification of prior
is intrinsically complicated and subjective [44]. The
main consideration is that the posterior mean and var-
iance should not depend on the units in which the dis-
ease similarities are measured and should also be
i n v a r i a n tt ot h es h i f to ft h eresponse variable. To meet
these requirements, the use of the Jeffreys prior [78]
could be considered, and a Markov chain Monte Carlo
(MCMC) approach could be adopted for the calculation
of the marginal likelihood.
Our approach can be further studied from the follow-
ing aspects. First, in addition to the domain-domain
interaction network, information such as annotations of
Pfam domains in the Gene Ontology (GO) can also pro-
vide a means for calculating similarities between
domains. Recently, methods for calculating semantic
similarities between GO terms have been packed into
user-friendly software [79]. It is therefore possible to
calculate pair-wise semantic similarities between every
two domains and then use this similarity profile with
our domainRBF model to infer associations between
domains and human inherited diseases.
Second, it is conceptually straightforward to extend
the domainRBF model to infer interactive effects of mul-
tiple domains on a query disease. For example, given a
query disease and a set of candidate domains, we can
enumerate all two-way combinations of the domains
and then use the DomainRBF model to infer possible
associations between the disease and interactions of two
domains. Nevertheless, such brute force method is com-
putationally intensive and not quite feasible in applica-
tion to the study of three-way or even higher order
interactive effects of candidate domains.
Third, with the accumulation of publicly available data
in genome-wide association (GWA) studies, we can
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dies. For example, given a disease of interest and a set
of candidate domains, we can prioritize the candidate
domains using our method and obtain the ranks of the
domains. On the other hand, given p- v a l u e so fS N P si n
a GWA study, we can obtain the statistical significance
of candidate domains in the GWA study by combining
the p-values of SNPs located in the domains and then
Figure 8 Modular organization of the predicted landscape of human disease phenotypes. (A) Two-way hierarchical clustering heat map
for the landscape of domain-phenotype associations. (B) Zoomed-in plot of the pink circle region in the heat map, involving 17 muscular
diseases and 20 related protein domains.
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Page 19 of 21prioritize the candidates to obtain their ranks. With
these two ranks, we can resort to statistical methods,
such as the one described in [8], to obtain a single rank
for each candidate domain.
Additional material
Additional file 1: Supplemental Figures. Supplemental Figure S1
shows the results of a series of permutation test using the large domain-
domain interaction network. Supplemental Figure S2 shows the mean
ranks for domains with different frequency of occurrence in human
proteins.
Additional file 2: Supplemental Tables. Supplemental Table S1 lists
contributions of seed domain-disease associations (leave-one-out cross-
validation experiments using the large domain-domain interaction
network). Supplemental Table S2 lists contributions of seed domain-
disease associations (ab initio prediction experiments using the small
domain-domain interaction network). Supplemental Table S3 lists
contributions of seed domain-disease associations (ab initio prediction
experiments using the large domain-domain interaction network).
Supplemental Table S4 lists the genome-wide evidence of associations
between domains and type 1 diabetes. Supplemental Table S5 lists the
genome-wide evidence of associations between domains and type 2
diabetes. Supplemental Table S6 lists the genome-wide evidence of
associations between domains and Crohn’s disease. Supplemental Table
S7 lists the genome-wide evidence of associations between domains and
breast cancer. Supplemental Table S8 lists contributions of seed domain-
disease associations in the analysis of the four disease examples.
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